E. Kolb

P. Rosenberg, H. Deeg, J. Tolar, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin‐bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)

J. Maris, P. Houghton, Malcolm A. Smith, 2015, Pediatric blood & cancer.

Targeting Glycoprotein NMB With Antibody‐Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma

P. Houghton, R. Gorlick, D. Geller, 2016, Pediatric blood & cancer.

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

David Haussler, Jacob Pfeil, Olena Morozova Vaske, 2019, Cell reports.

A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia

P. Steinherz, E. Kolb, 2003, Leukemia.

Combination testing (Stage 2) of the Anti‐IGF‐1 receptor antibody IMC‐A12 with rapamycin by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing of JNJ‐26854165 (Serdemetan) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing (stage 1) of the investigational mTOR kinase inhibitor MLN0128 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myeloid Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy.

M. Sulis, J. Chewning, S. Meshinchi, 2022, Transplantation and cellular therapy.

Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia

S. Barwe, E. Bonvini, J. Davidson-Moncada, 2022, Journal of clinical medicine.

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG

T. Alonzo, R. Gerbing, D. Reinhardt, 2021, Cancers.

Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group

D. Reinhardt, J. Starý, J. Bourquin, 2020, Cancers.

Outcomes of intensification of induction chemotherapy for children with high‐risk acute myeloid leukemia: A report from the Children's Oncology Group

S. Meshinchi, T. Alonzo, R. Gerbing, 2021, Pediatric blood & cancer.

Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group

D. Johnston, H. Bittencourt, N. Hijiya, 2019, Pediatric blood & cancer.

Initial testing of dasatinib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Cytarabine dose reduction in patients with low‐risk acute myeloid leukemia: A report from the Children's Oncology Group

S. Raimondi, S. Meshinchi, T. Alonzo, 2021, Pediatric blood & cancer.

Bone marrow transplant and pediatric multiple myeloma

A. Walter, E. Kolb, Kimberly A Davidow, 2018, Pediatric blood & cancer.

Modeling Transient Abnormal Myelopoiesis Using Induced Pluripotent Stem Cells and CRISPR/Cas9 Technology

Anilkumar Gopalakrishnapillai, S. Barwe, E. Kolb, 2020, Molecular therapy. Methods & clinical development.

Initial testing of VS‐4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2017, Pediatric blood & cancer.

Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Fully Human Monoclonal Antibody Targeting IGF-1 R , Is Effective Alone and in Combination With Rapamycin in Inhibiting Growth of Osteosarcoma Xenografts

P. Houghton, R. Gorlick, Juan Lin, 2010 .

Initial testing (stage 1) of the phosphatidylinositol 3′ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Initial testing of lenalidomide by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Initial testing (Stage 1) of the antibody‐maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Initial testing (stage 1) of LCL161, a SMAC mimetic, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Intracranial hemorrhage in alloimmune thrombocytopenia: stratified management to prevent recurrence in the subsequent affected fetus.

R. Berkowitz, J. Bussel, E. Kolb, 2009, American journal of obstetrics and gynecology.

CD81 knockout promotes chemosensitivity and disrupts in vivo homing and engraftment in acute lymphoblastic leukemia.

Anthony Quagliano, Anilkumar Gopalakrishnapillai, S. Barwe, 2020, Blood advances.

Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF‐1 receptor by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Morphologic remission status is limited compared to ΔN flow cytometry: a Children's Oncology Group AAML0531 report.

S. Meshinchi, T. Alonzo, R. Gerbing, 2020, Blood advances.

Children's Mercy Kansas City

S. Meshinchi, T. Alonzo, R. Gerbing, 2020 .

Preclinical Analysis of Tasidotin HCl in Ewing's Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, and Osteosarcoma

Mimi Kim, E. Kolb, Wendong Zhang, 2007, Clinical Cancer Research.

The B7-H3–Targeting Antibody–Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models

S. Seaman, J. Maris, B. Teicher, 2021, Clinical Cancer Research.

Vorinostat Enhances Cytotoxicity of SN-38 and Temozolomide in Ewing Sarcoma Cells and Activates STAT3/AKT/MAPK Pathways

E. Kolb, D. Loeb, Valerie B. Sampson, 2015, PloS one.

Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania

E. Puffenberger, E. Crowgey, E. Kolb, 2019, The Journal of molecular diagnostics : JMD.

Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia.

R. Ries, S. Meshinchi, T. Alonzo, 2021, Blood advances.

Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.

G. Leverger, R. Ribeiro, D. Reinhardt, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The pediatric preclinical testing program: Description of models and early testing results

Joseph Zeidner, Javed Khan, Jian Zhang, 2007, Pediatric blood & cancer.

Initial testing of the aurora kinase a inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP)

Peter J Houghton, John M Maris, Richard Gorlick, 2010, Pediatric blood & cancer.

Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group

S. Raimondi, S. Meshinchi, T. Alonzo, 2020, Haematologica.

Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium

B. Teicher, P. Houghton, Malcolm A. Smith, 2020, Pediatric blood & cancer.

Testing of the Akt/PKB inhibitor MK‐2206 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

S. Keir, J. Maris, P. Houghton, 2011, Cancer Chemotherapy and Pharmacology.

Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra‐cranial solid tumors: A Children's Oncology Group Phase I Consortium report

C. Ahern, T. Cripe, B. Weigel, 2015, Pediatric blood & cancer.

Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031

S. Raimondi, S. Meshinchi, T. Alonzo, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia

Anne-Katrin Emde, D. Gerhard, Heather Geiger, 2018, bioRxiv.

Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia: A report from the TARGET initiative

Anne-Katrin Emde, D. Gerhard, Heather Geiger, 2018, bioRxiv.

Distinct age-associated molecular profiles in acute myeloid leukemia defined by comprehensive clinical genomic profiling

P. Stephens, D. Lipson, V. Miller, 2018, Oncotarget.

Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

S. Raimondi, R. Ries, S. Meshinchi, 2017, Clinical Cancer Research.

Initial testing (stage 1) of the histone deacetylase inhibitor, quisinostat (JNJ‐26481585), by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions

Hamid Bolouri, Xiaotu Ma, Jinghui Zhang, 2017, Nature Medicine.

The Microtubule Network and Cell Death Are Regulated by an miR-34a/Stathmin 1/βIII-Tubulin Axis

E. Kolb, Valerie B. Sampson, N. Vetter, 2017, Molecular Cancer Research.

A phase II study of eribulin in recurrent or refractory osteosarcoma: A report from the Children's Oncology Group

R. Goldsby, K. Janeway, R. Gorlick, 2018, Pediatric blood & cancer.

Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis.

Peter J Houghton, John M Maris, Richard Gorlick, 2016, Cancer research.

Ecteinascidin-743 inhibits activated but not constitutive transcription.

K. Scotto, E. Kolb, D. Friedman, 2002, Cancer research.

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML Study

H. Bolouri, K. Loeb, T. Triche, 2019, Clinical Cancer Research.

Initial Testing (Stage 1) of MK‐8242—A Novel MDM2 Inhibitor—by the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2016, Pediatric blood & cancer.

MicroRNAs and Potential Targets in Osteosarcoma: Review

E. Anders Kolb, J. Yustein, Subbaya Subramanian, 2015, Front. Pediatr..

Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research.

D. Reinhardt, C. Zwaan, A. L. Frazier, 2021, JCO clinical cancer informatics.

Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Initial testing of the MDM2 inhibitor RG7112 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2013, Pediatric blood & cancer.

Xenograft and genetically engineered mouse model systems of osteosarcoma and Ewing's sarcoma: tumor models for cancer drug discovery

E. Kolb, Valerie B. Sampson, D. Kamara, 2013, Expert opinion on drug discovery.

Initial testing (Stage 1) of TAK‐701, a humanized hepatocyte growth factor binding antibody, by the pediatric preclinical testing program

J. Maris, P. Houghton, Malcolm A. Smith, 2014, Pediatric blood & cancer.

Delivery of care consistent with the psychosocial standards in pediatric cancer: Current practices in the United States

A. Kazak, F. Chen, Kimberly S. Canter, 2018, Pediatric blood & cancer.

Implementing the psychosocial standards in pediatric cancer: Current staffing and services available

A. Kazak, F. Chen, Kimberly S. Canter, 2017, Pediatric blood & cancer.

Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway.

J. Healey, R. Gorlick, P. Meyers, 2004, Cancer research.

Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program

S. Keir, J. Maris, P. Houghton, 2014, Clinical Cancer Research.

Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2017, Pediatric blood & cancer.

Parallel Randomized Trials of Risk-Based Therapy for Fetal Alloimmune Thrombocytopenia

R. Berkowitz, J. Bussel, M. Lesser, 2006, Obstetrics and gynecology.

Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673

S. Keir, J. Maris, O. Hampton, 2015, Pediatric blood & cancer.

Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17‐DMAG, KOS‐1022) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Mesothelin: An Immunotherapeutic Target beyond Solid Tumors

S. Barwe, E. Kolb, Anilkumar Gopalakrishnapillai, 2022, Cancers.

Long Noncoding RNA Expression Independently Predicts Outcome in Pediatric Acute Myeloid Leukemia

R. Ries, S. Meshinchi, T. Alonzo, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blood Count Recovery Following Induction Therapy for Acute Myeloid Leukemia in Children Does Not Predict Survival

T. Alonzo, R. Gerbing, M. Loken, 2022, Cancers.

CEBPA bZip Mutations are Associated with Favorable Prognosis in de novo AML: A Report from the Children's Oncology Group.

R. Ries, S. Meshinchi, T. Alonzo, 2021, Blood.

Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options — a COG and Target Pediatric AML Study

H. Bolouri, R. Ries, S. Meshinchi, 2018, Blood.

MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia

D. Gerhard, E. Pleasance, M. Marra, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comprehensive characterization of pediatric AML reveals diverse fusion oncoproteins and age-specific mutational interactions

Richard A. Moore, Stephen R. Piccolo, D. Gerhard, 2017 .

The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions

Richard A. Moore, Stephen R. Piccolo, D. Gerhard, 2017, bioRxiv.

Insulin-Like Growth Factor 1 Receptor and Response to Anti-IGF1R Antibody Therapy in Osteosarcoma

P. Houghton, P. Rao, Yu Cao, 2014, PloS one.

Gemtuzumab Ozogamicin Improves Event-Free Survival and Reduces Relapse in Pediatric KMT2A-Rearranged AML: Results From the Phase III Children's Oncology Group Trial AAML0531

S. Raimondi, S. Meshinchi, T. Alonzo, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acute myeloid leukemia in children and adolescents: identification of new molecular targets brings promise of new therapies.

S. Meshinchi, E. Kolb, 2015, Hematology. American Society of Hematology. Education Program.

Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults.

A. Huvos, J. Healey, C. Laverdière, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of GATA1 and STAG2 Mutations in Induced Pluripotent Stem Cells with Trisomy 21

S. Barwe, A. Sebastian, E. Kolb, 2022, Cells.

CRISPR/Cas9-Directed Reassignment of the GATA1 Initiation Codon in K562 Cells to Recapitulate AML in Down Syndrome

E. Kmiec, Anilkumar Gopalakrishnapillai, E. Kolb, 2017, Molecular therapy. Nucleic acids.

Long-Term E vent-Free S urvival A fter I ntensive C hemotherapy for E wing's F amily o f T umors i n C hildren a nd Y oung A dults

A. Huvos, J. Healey, C. Laverdière, 2003 .

Successful outcome with tandem myeloablative chemotherapy and autologous peripheral blood stem cell transplants in a patient with atypical teratoid/rhabdoid tumor of the central nervous system

A. Levy, E. Kolb, J. Goodrich, 2008, Journal of Neuro-Oncology.

Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group

B. Crompton, D. Rakheja, Helen X. Chen, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of a phase 2, multicenter, single‐arm, open‐label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia

T. Alonzo, P. Brown, J. Levine, 2021, Pediatric blood & cancer.

The Combination of Clofarabine and Cytarabine in Pediatric Relapsed Acute Lymphoblastic Leukemia: A Case Report

E. Kolb, Yingxian Liu, K. Ramesh, 2008, Chemotherapy.

FLT3 Mutations in Pediatric Acute Promyelocytic Leukemia; A Report from the Children's Oncology Group AAML0631 Trial

S. Meshinchi, T. Alonzo, R. Gerbing, 2016 .

Imetelstat Induces Leukemia Stem Cell Death in Pediatric Acute Myeloid Leukemia Patient-Derived Xenografts

S. Barwe, E. Kolb, Fei Huang, 2022, Journal of clinical medicine.

Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ‐secretase inhibitor targeting notch signaling

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Initial testing of the CENP‐E inhibitor GSK923295A by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Risk factors for chemotherapy‐induced nausea in pediatric patients receiving highly emetogenic chemotherapy

J. Krischer, K. Kelly, O. J. Sahler, 2019, Pediatric blood & cancer.

The neuroradiological findings in a case of Revesz syndrome

Y. Lui, M. Scheinfeld, J. Bello, 2007, Pediatric Radiology.

Development of IGF-IR inhibitors in pediatric sarcomas

R. Gorlick, E. Kolb, E. A. Kolb, 2009, Current oncology reports.

A 3-D hydrogel based system for hematopoietic differentiation and its use in modeling down syndrome associated transient myeloproliferative disorder.

Anilkumar Gopalakrishnapillai, S. Barwe, K. Kiick, 2021, Biomaterials science.

The Addition of Bortezomib to Standard Chemotherapy for Pediatric Acute Myeloid Leukemia Has Increased Toxicity without Therapeutic Benefit: A Report from the Children's Oncology Group

S. Raimondi, S. Meshinchi, T. Alonzo, 2016 .

Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Strong concordance between RNA structural and single nucleotide variants identified via next generation sequencing techniques in primary pediatric leukemia and patient-derived xenograft samples

T. Druley, E. Crowgey, S. Barwe, 2020, Genomics & informatics.

Development of acute lymphoblastic leukemia following treatment for acute myeloid leukemia in children with Down syndrome: A case report and retrospective review of Children's Oncology Group acute myeloid leukemia trials

T. Alonzo, R. Gerbing, R. Wells, 2019, Pediatric blood & cancer.

Molecular and phenotypic diversity of CBLmutated juvenile myelomonocytic leukemia

M. Loh, A. Olshen, M. Sulis, 2020, Haematologica.

Initial testing of the replication competent Seneca Valley virus (NTX‐010) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2010, Pediatric blood & cancer.

Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial

C. Minard, Erin H. Breese, S. Tasian, 2022, Blood.

CD123 Expression Is Associated With High-Risk Disease Characteristics in Childhood Acute Myeloid Leukemia: A Report From the Children's Oncology Group

S. Meshinchi, T. Alonzo, M. Loken, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mesothelin Expression Is Associated with Extramedullary Disease and Promotes In Vivo Leukemic Growth in Acute Myeloid Leukemia

R. Ries, S. Meshinchi, T. Alonzo, 2020 .

Initial testing (stage 1) of the notch inhibitor PF‐03084014, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2014, Pediatric blood & cancer.

Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy.

E. Kolb, Valerie B. Sampson, C. C. Mills, 2018, Cancer research.

Systemic administration of reovirus (Reolysin) inhibits growth of human sarcoma xenografts

C. Guha, Juan Lin, E. Kolb, 2011, Cancer.

Immunotherapeutic Targeting of Mesothelin Positive Pediatric AML Using Bispecific T Cell Engaging Antibodies

S. Meshinchi, C. Correnti, A. Bandaranayake, 2021, Cancers.

Mesothelin Targeting Bites for Pediatric AML: In Vivo Efficacy and Specificity

S. Meshinchi, C. Correnti, Anilkumar Gopalakrishnapillai, 2019, Blood.

Immunotherapeutic Targeting of Mesothelin in Acute Myeloid Leukemia in Vitro with Anetumab Ravtansine and a Novel Antibody-Drug Conjugate

S. Meshinchi, E. Kolb, Katherine Tarlock, 2018, Blood.

Discovery and Validation of Cell-Surface Protein Mesothelin (MSLN) As a Novel Therapeutic Target in AML: Results from the COG/NCI Target AML Initiative

D. Gerhard, M. Marra, A. Mungall, 2016 .

Transcriptome Profiling of Glycosylation Genes Defines Correlation with E-Selectin Ligand Expression and Clinical Outcome in AML

R. Ries, S. Meshinchi, T. Alonzo, 2019, Blood.

Opportunities for expanding clinical trial enrollment for relapsed and refractory pediatric acute myeloid leukemia in the United States and Canada

N. Bhakta, J. Rubnitz, E. Kolb, 2017, Pediatric blood & cancer.

Hypodiploidy has unfavorable impact on survival in pediatric acute myeloid leukemia: an I-BFM Study Group collaboration

S. Raimondi, G. Leverger, T. Taki, 2022, Blood advances.

Initial testing (stage 1) of the BH3 mimetic ABT‐263 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

AAML 1421, a phase I/II study of CPX-351 followed by fludarabine, cytarabine, and G-CSF (FLAG) for children with relapsed acute myeloid leukemia (AML): A Report from the Children’s Oncology Group.

T. Alonzo, R. Gerbing, M. Absalon, 2019, Journal of Clinical Oncology.

Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile

R. Ries, S. Meshinchi, T. Alonzo, 2019, Blood.

Prognostic Significance of 11q23/MLL Fusion Partners in Children with Acute Myeloid Leukemia (AML) - Results from the Children's Oncology Group (COG) Trial AAML0531

S. Raimondi, S. Meshinchi, T. Alonzo, 2016 .

Down syndrome and AML: where do we go from here?

E. Kolb, D. Tomizawa, 2017, Blood.

Structural Variants Involving MLLT10/AF10 Are Associated with Adverse Outcome in AML Regardless of the Partner Gene - a COG/Tpaml Study

S. Raimondi, T. Triche, R. Ries, 2019, Blood.

Genomic Subtypes of Nucleophosmin (NPM1) Mutations Are Associated with Clinical Outcome in AML - a COG and SWOG Intergroup Collaboration

J. Radich, S. Meshinchi, T. Alonzo, 2016 .

ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium

B. Teicher, Malcolm A. Smith, R. Gorlick, 2020, Molecular Cancer Therapeutics.

Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program

S. Keir, L. Rubinstein, J. Maris, 2010, Molecular Cancer Therapeutics.

Initial testing (stage 1) of SGI‐1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial.

S. Raimondi, S. Meshinchi, R. Gerbing, 2021, JAMA oncology.

Acupressure bands do not improve chemotherapy‐induced nausea control in pediatric patients receiving highly emetogenic chemotherapy: A single‐blinded, randomized controlled trial

J. Krischer, K. Kelly, O. J. Sahler, 2018, Cancer.

Initial testing (stage 1) of temozolomide by the pediatric preclinical testing program

Peter J Houghton, John M Maris, Richard Gorlick, 2013, Pediatric blood & cancer.

Initial testing of the hypoxia‐activated prodrug PR‐104 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2011, Pediatric blood & cancer.

Initial testing (stage 1) of mapatumumab (HGS‐ETR1) by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2009, Pediatric blood & cancer.

Clinical relevance of proteomic profiling in de novo pediatric acute myeloid leukemia: a Children’s Oncology Group study

Chenyue W. Hu, R. Ries, A. Qutub, 2022, Haematologica.

p27/Kip1 functions as a tumor suppressor and oncoprotein in osteosarcoma

R. Gorlick, V. Gopalakrishnan, E. Kolb, 2019, Scientific Reports.

High-dose AraC is Essential for the Treatment of ML-DS Independent of Post-Induction MRD: Results of COG AAML1531.

S. Raimondi, T. Druley, T. Alonzo, 2021, Blood.

A psychosocial clinical care pathway for pediatric hematopoietic stem cell transplantation

Naomi E Joffe, J. Chewning, J. Deatrick, 2019, Pediatric blood & cancer.

Initial testing (stage 1) of glembatumumab vedotin (CDX‐011) by the pediatric preclinical testing program

P. Houghton, R. Gorlick, C. Billups, 2014, Pediatric blood & cancer.

Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2012, Pediatric blood & cancer.

CREBBP Alterations are Associated with A Poor Prognosis in de novo AML.

R. Ries, Pandurang Kolekar, S. Meshinchi, 2021, Blood.

Bortezomib is significantly beneficial for de novo pediatric AML patients with low phosphorylation of the NF‐κB subunit RelA

S. Meshinchi, T. Alonzo, R. Gerbing, 2021, Proteomics. Clinical applications.

A Phase 2 Trial of KIR Mismatched Unrelated Donor Transplantation Using In Vivo T-cell Depletion with ATG in AML: Children's Oncology Group AAML05P1 Study.

S. Meshinchi, T. Alonzo, R. Gerbing, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program

S. Keir, J. Maris, P. Houghton, 2008, Pediatric blood & cancer.

Evaluating the Efficacy of PRMT5 Inhibitor C220 in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia

Anilkumar Gopalakrishnapillai, S. Barwe, P. Scherle, 2021, Blood.

Screening for Family Psychosocial Risk in Pediatric Hematopoietic Stem Cell Transplantation with the Psychosocial Assessment Tool.

Naomi E Joffe, J. Chewning, W. Hwang, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Revised Risk Stratification Criteria for Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group

S. Raimondi, R. Ries, S. Meshinchi, 2017 .

Disruption of Annexin II /p11 Interaction Suppresses Leukemia Cell Binding, Homing and Engraftment, and Sensitizes the Leukemia Cells to Chemotherapy

A. Napper, Anilkumar Gopalakrishnapillai, S. Barwe, 2015, PloS one.

Reolysin®, an unmodified Reovirus, has significant anti-tumor activity in childhood sarcomas

E. Kolb, Wendong Zhang, 2006 .

Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine–Panobinostat Combination

S. Barwe, E. Kolb, Anilkumar Gopalakrishnapillai, 2023, Cancers.

Newly Diagnosed Childhood AML Patients Treated with Bortezomib Show Superior Survival If CD74 Is Expressed: A Report of 991 Patients from the Children's Oncology Group AAML1031 Protocol

S. Meshinchi, T. Alonzo, R. Gerbing, 2020 .

A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML)

A. DeCillis, C. Zwaan, E. Kolb, 2019, Blood.